You are here

AbbVie

This Blockbuster Drug's Latest News Could Be Another Home Run for AbbVie

Motley Fool

Fri, 03/31/23 - 10:16 am

clinical trials

ulcerative colitis

AbbVie sidelines CytomX after seeing midphase oncology ADC data, opens talks on returning lead drug

Fierce Biotech

Tue, 03/28/23 - 10:22 am

CytomX Therapeutics

antibody-drug conjugate

Top 10 pharma R&D budgets in 2022

Fierce Biotech

Mon, 03/27/23 - 10:21 pm

Bristol Myers Squibb

AbbVie clinches back-to-back clinical wins in ulcerative colitis, lupus

BioSpace

Fri, 03/24/23 - 11:50 am

ulcerative colitis

clinical trials

AbbVie's Skyrizi aces ulcerative colitis study en route to new IBD showdown with J&J, Takeda

Fierce Pharma

Thu, 03/23/23 - 11:39 am

ulcerative colitis

clinical trials

AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa

EP Vantage

Tue, 03/21/23 - 09:54 am

hidradenitis suppurativa

AbbVie’s Skyrizi hits the spot in refractory psoriasis

Pharmaphorum

Mon, 03/20/23 - 11:21 am

AbbVie's Humira, 5 Pfizer drugs among those with price hikes that exceeded inflation rate

Fierce Pharma

Wed, 03/15/23 - 11:25 am

AbbVie braces for 'greater erosion' of Humira franchise in second half of this year

Endpoints

Tue, 03/7/23 - 10:22 pm

AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff

Fierce Pharma

Tue, 03/7/23 - 11:55 am

Richard Gonzalez

AbbVie and Capsida Biotherapeutics partner on eye disease focused gene therapies

Biopharma Reporter

Mon, 02/27/23 - 09:59 am

Capsida Biotherapeutics

drug development

AbbVie, Capsida Set Sights on Gene Therapies for Eye Diseases

BioSpace

Thu, 02/23/23 - 10:02 am

Capsida Biotherapeutics

Big pharma’s looming threat: a patent cliff of ‘tectonic magnitude’

BioPharma Dive

Tue, 02/21/23 - 11:05 am

Bristol Myers Squibb

Years after the first US biosim launches, doctors still have their concerns: survey

Fierce Pharma

Thu, 02/16/23 - 04:49 pm

The world needs Garp, according to Abbvie

EP Vantage

Fri, 02/10/23 - 10:20 am

AbbVie talks next steps as first Humira competitor makes it to market

Endpoints

Thu, 02/9/23 - 06:01 pm

AbbVie opens up to bigger deals as competition heats up

Endpoints

Mon, 02/6/23 - 06:19 pm

After AbbVie, Teva walks away from influential trade group PhRMA

Fierce Pharma

Mon, 02/6/23 - 10:32 am

Teva Pharmaceutical

Amgen Adopts A Two-Price Strategy For The U.S.’s First Marketed Humira-Referenced Biosimilar, Amjevita

Forbes

Wed, 02/1/23 - 10:41 am

Amgen launches Humira biosimilar, releases Q4 earnings report

Medical Marketing and Media

Tue, 01/31/23 - 11:21 pm

Pages